Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

This guidance re-emphasises the importance of discussing all ER-ve and HER2+ve breast cancer patients in the pre-operative MDT

Classifications: Adjuvant & Neoadjuvant Treatment

Keywords: Neoadjuvant Chemotherapy/ NACT